Create your personal agenda –check the favourite icon
Workshop A: Funding & Investment for Animal Health
Keynotes
What investment opportunities are there to support innovation in the animal health biologics field? Attend this workshop to hear about how to secure funding and create strategic partnerships from private and public funding bodies as well as the big pharma leading the industry.
Scott Sellers, Department for Environment Food and Rural AffairsUnited Kingdom
Dr Nigel Swift, Global Head Of Vaccine Research And Development, Boehringer IngelheimUnited Kingdom
Workshop B: Vaccine Market Access and Regulatory Affairs for Global Health
Keynotes
The market for vaccines is more complex than most and there are many definitions of what constitutes a healthy market – one that ensures sustainable, sufficient, relevant, predictable supply to meet demand. There are a complex, interconnected set of factors that together comprise the market place, including the regulatory environment, the incentives or disincentives for investing in new innovation and R&D, how the value of vaccines are assessed, the procurement of vaccines, as well as the infrastructure for delivery of and access to vaccines. How global, regional, and national stakeholders, including government authorities, multi-laterals, NGOs, and industry, make decisions and act in the marketplace can determine the health or the fragility of the vaccine market in the short and long-term. This session will explore what we mean by a healthy vaccine market, the various factors that comprise the market, and factors that can enable or impede a healthy market.
- Overview of global vaccine market and describing the characteristics of a healthy market (review of current frameworks)
- Insights from the introduction of new vaccines and strategies that have been leveraged to encourage sustainable, sufficient, relevant, predictable supply to meet demand – what’s worked and what hasn’t in different contexts, including LMICs
- Opportunities for greater collaboration across stakeholders, including industry, to think holistically about vaccine markets and address key challenges that undermine the health of the market
Moderator: Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, MSDUnited States
Ariane Mccabe, Director, Global Health And Public Affairs, GlaxoSmithKlineSwitzerland
Workshop C: Active & passive immunity: How do we induce maternal immunisation in human and animals?
Keynotes
Maternal immunity plays a pivotal role in human & animal health, but what do we understand? Is the veterinary vaccine industry more advanced than human? What can we learn from each other to move the field forward?
Oliver Gomez-Duran, Head Of Technical, Boehringer Ingelheim Animal HealthGermany
Workshop D: Improvement of cancer patient treatment outcomes: Using liquid biopsies & novel biomarkers for predicting prognosis and response
Keynotes
Biomarker Strategy
Moderator: Prof Karen-Lise Spindler, Aarhus UniversityDenmark
Tony Whetton, Director, Stoller Biomarker Discovery CentreUnited Kingdom
Dr Yong-Jie Lu, Professor In Molecular Oncology, Queen Mary University of LondonUnited Kingdom
Create your personal agenda –check the favourite icon
Chair’s opening remarks
Keynotes
Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics
Keynotes
- How are we incentivizing vaccine development?
- How will these vaccines reach the LMICs and developing countries?
- CEPI’s strategy and investment to advance medical countermeasures to emerging diseases
- The potential of translational medicine and access for all
- How to secure public funding to advance research and vaccine development
Are we pandemic ready for influenza? How to close the gaps in our current strategy in preparedness
Keynotes
- How to close the gaps in our current strategy in preparedness
- What is our response mechanism in medical and non-medical interventions?
- European wide actions to provide global health, sustainable policies, coverage and access – joint procurement
- The role of industry in vaccine matching, manufacturing and antivirals
Ann Moen, Chief, World Health OrganisationSwitzerland
What will 2020 hold for immuno-oncology? A global landscape and overview of promising approaches
Keynotes
- Emerging immuno-oncology targets and modalities
- Exploring possible uses of artificial intelligence in oncology (patient stratification, predicting patient response to treatment, AI as a diagnostic tool etc)
- Ensuring patient centricity in oncology clinical trials
- Looking to the future: How can we go further to make precision medicine a reality for cancer patients?
African Swine Fever: Ensuring a cross-sectorial collaboration in tackling the disease
Keynotes
- Challenges in Phase IV studies and register based impact research
- Post-licensure safety studies using real world data
CEPI: CFP2 rolling call
Keynotes
Challenges of universal influenza vaccines evaluation
Keynotes
Development pathways for combining immune-based therapies in cancer: leveraging disease biology, complex biomarkers, regulatory approval and pathways to adoption
Keynotes
Do we understand the biology behind cold and hot tumours, which is needed for successful treatment and what is the role for biomarkers?
Keynotes
Establishing a One Health approach to combat emerging zoonotic & transboundary diseases
Keynotes
Further follow up on: Are we pandemic ready for influenza? How to close the gaps in our current strategy in preparedness
Keynotes
Further follow up on: Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics
Keynotes
Human Challenge studies: Dengue, Zika, Ebola: How far can we go?
Keynotes
Strengthening human & animal public health systems at their interface to prevent AMR: Spanish National Action Plan against Antimicrobial Resistance
Keynotes
Treating companion animal diseases: Bringing cutting edge human technologies to the animal health space
Keynotes
- Challenges in Phase IV studies and register based impact research
- Post-licensure safety studies using real world data
Unique Operational Challenges for Vaccines Clinical Development.
Keynotes
Virtual trials—do they have a role in vaccine studies
Keynotes
Chair’s opening remarks
Influenza & Respiratory
Chair’s opening remarks
Immuno-oncology
Chair’s opening remarks
Veterinary
Chair’s opening remarks
Emerging Diseases
Jakob Cramer, Head Of Clinical Development, CEPI
Chair’s opening remarks
New Technology
Chair’s opening remarks
AMR
Chair's opening remarks
Companion Animals
Patrick Frayssinet, R&D Director, URODELIAFrance
Applying HIV vaccine development to Lassa
New Technology
Developing novel combination immunotherapies for cervical cancer and head-and-neck cancer
Immuno-oncology
- Clinical Updates on Phase II trial ISA101b and cemiplimab
Epidemic preparedness with humanised animal vaccines
Veterinary
- MERS, RVF & FLU
The first EMA approved veterinary stem cell therapy: Ubi Sumus, Quo Vadimus?
Companion Animals
(Where are we and where are we going to)
The tortuous path of dengue vaccine development
Emerging Diseases
WHO recommendations for Dengvaxia
Update on VRC flu vaccine trials
Influenza & Respiratory
Vaccines as a tool to combat AMR
AMR
Dengue vaccine trials in development
Emerging Diseases
Ricardo Palacios, Instituto ButantanBrazil
Exploring the crossover between human and veterinary applications for stem cells
Companion Animals
Harmonising priorities in Europe: Role of public health, government strategies and industry to halting the AMR crisis – do we have a consistent message?
AMR
Insight and progress from international healthcare agencies; How can regulatory and access policies can be used to strengthen utilization of vaccines in our international action plans to address AMR?
Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, MSDUnited States
Bryan Deane, New Medicines, ABPIUnited Kingdom
Hope for late-stage ovarian cancer: Development of a personalized dendritic cell vaccine
Immuno-oncology
Update in the clinical development of a plant-derived quadrivalent Virus-Like Particles influenza vaccine
Influenza & Respiratory
Working towards control and eradication of African swine fever (ASF) in the EU
Veterinary
African swine fever virus antigen discovery
Veterinary
Collaborative efforts with WRAIR on the development of an inactivated Zika vaccine
Emerging Diseases
Developing species-specific therapeutic monoclonal antibodies that address the demand for innovative therapies for companion animals
Companion Animals
New on the block: Ph1 trial results on a Chikungunya vaccine candidate
New Technology
A new vaccine based on recombinant viral vectors
New perspectives for influenza vaccine assessment
Influenza & Respiratory
Next generation mRNA cancer vaccine approaches and intratumoral immunomodulation
Immuno-oncology
Chikungunya in clinical development – an update & Update on our first CEPI program with Lassa and MERS
New Technology
Call to action: How the innovative vaccines industry is contributing to fight against AMR
AMR
Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, MSDUnited States
Clinical Updates: Development of effective vaccines approaches against African swine fever virus
Veterinary
Next generation companion animal therapeutic biologics and manufacturing
Companion Animals
Overcoming current limitations in selecting immunogenic neoantigens- The NeoScreen platform
Immuno-oncology
Overview of the Ebola vaccine results from the 2013 – 2016 outbreak, the requirement for improvements in the field
Emerging Diseases
VaXIMISER – new eggs and cells for maximising vaccine production
Influenza & Respiratory
Andrew Bean, Chief Technology Officer, Commonwealth Scientific and Industrial Research OrganisationAustralia
Alternative needle-free delivery devices advancing vaccine development
New Technology
New flu data towards a universal flu vaccine
Influenza & Respiratory
A DNA vaccine against MERS vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study
New Technology
AMR: Overcoming hurdles to increase the vaccination of animals
Veterinary
Building international capacity to tackle AMR more efficiently – is this in line with Europe?
AMR
Stewardship & social behaviour change in Europe – do we have measurable push & pull outcomes?
Dr Erin Duffy, Chief of Research and Development, CARB-XUnited States
eVLPs as an antigen delivery & immunomodulatory platform in cancer
Immuno-oncology
New immune-data and correlates analysis on our Ebola vaccine
Emerging Diseases
Dr Benoit Callendret, Cdtl, Janssen VaccinesNetherlands
The Human Vaccines Project: Efforts towards a Universal flu vaccine
Influenza & Respiratory
What has all this data told us?
The use of vaccination to treat chronic allergic diseases in companion animals
Companion Animals
Stewardship & social behaviour change in Europe – do we have measurable push & pull outcomes?
Martin Bachmann, Professor of Immunology, University of BernSwitzerland
Autologous therapeutic cancer vaccine from companion animal to human
Companion Animals
Patrick Frayssinet, R&D Director, URODELIAFrance
Characterizing immune signatures to malaria for better correlates of protection
Emerging Diseases
What the long-term effect and longevity of RTSS vaccine?
NousCom neoantigen-based cancer vaccine for potent and effective anti-tumor T cell immunity
Immuno-oncology
Photochemical internalisation (fimaVacc) – a novel technology for enhancing cellular immune responses with protein and peptide based vaccines
New Technology
Rift Valley fever vaccines: current and future needs
Veterinary
Universal flu vaccine candidate
Influenza & Respiratory
Development of new adjuvants for oral vaccines, study of their mechanism of action and uses thereof
New Technology
First phase I results from a novel universal flu vaccine candidate?
Influenza & Respiratory
Create your personal agenda –check the favourite icon
Chair’s opening remarks
Influenza & Respiratory
Chair’s opening remarks
Immuno-oncology
Chair’s opening remarks
Veterinary
Chair’s opening remarks
Emerging Diseases
Jerry Sadoff, Senior Advisor, JanssenNetherlands
Chair’s opening remarks
AMR
Chair’s opening remarks
Bioprocess & Manufacture
From a mathematical model to a novel universal influenza vaccine
Bioprocess & Manufacture
Sunetra Gupta, Professor, University of OxfordUnited Kingdom
Immunotherapy in 2020: Beyond checkpoint inhibition and CAR T cells
Immuno-oncology
New reverse genetics systems to complement the RSV toolbox: Preclinical and clinical tools
Influenza & Respiratory
Martin Ludlow, Group Leader, Research Center for Emerging Infections and Zoonoses (RIZ)Germany
Pandemic preparedness - How to proceed in the absence of an outbreak?
Emerging Diseases
Examples from Ebola and Zika
Dr Marco Cavaleri, Head Of Anti-Infectives And Vaccines, EMAUnited Kingdom
Summary of Day 1 AMR talks
AMR
With the increase in novel vaccine and other biotherapeutic technologies in development – is the regulatory framework ready?
Veterinary
Formulation considerations for the development of adjuvanted vaccines
Bioprocess & Manufacture
How do we overcome adoptive cell therapy limitations to enable the treatment of more patients?
Immuno-oncology
- Novel approach to target solid tumours
RSV adaptive immunity assays: what do we need?
Influenza & Respiratory
The transfer of AMR bacteria between humans and animals and where we can interfere the best (and what the result can be)
AMR
Development of novel S2 insect cell lines enabling production of improved vaccines
Bioprocess & Manufacture
Engineering of African Swine Fever virus for production of live attenuated vaccine candidates
Veterinary
MERS and Lassa vaccines development
Emerging Diseases
Rational development of functionalized nanobiomaterials as novel immunotherapies for cancer treatment
Immuno-oncology
The ferret as an animal model to study Respiratory Syncytial Virus infection, transmission and countermeasures
Influenza & Respiratory
The impact of PCV13 in Capita on non bacteremic pneumonia and how to improve on efficacy
AMR
Will conjugates on alum suffice?
Affinity chromatography for vaccines purification: EU DiViNe project provides proof of concept
Bioprocess & Manufacture
Fill & finish of live vaccines – A CDMO perspective
Bioprocess & Manufacture
Insight on future combination strategies
Immuno-oncology
- Are we effectively incorporating profiling techniques into R&D to better understand the underlying cellular mechanisms and “build” better combinations?
Next-generation adjuvants: Transferring the learnings of its use in humans to veterinary health, an African perspective
Veterinary
Progress made in TB vaccines
AMR
Could we halve global tuberculosis rates?
Progress on CMV vaccines and antibody therapies
Emerging Diseases
- Development of a CMV vaccine based on non-replicating lymphocytic choriomeningitis virus vectors
- PhII data on a MVA based vaccine for the transplant space
- Title TBC
Update on Janssen RSV vaccine and use of human RSV challenge model
Influenza & Respiratory
Dr Benoit Callendret, Cdtl, Janssen VaccinesNetherlands
Cancer genomics and immunotherapy: predicting response and illuminating disease biology
Immuno-oncology
Flexible and scalable strategies for vaccine processing from development to manufacturing supported by integrated process analytical technologies
Bioprocess & Manufacture
Large animal challenge models for assessment of human and veterinary negative strand virus recombinant vaccines
Veterinary
Ph 3 RSV F nanoparticle maternal RSV vaccine
Influenza & Respiratory
Clinical development of a live-attenuated RSV vaccine – Update on Phase I results
Influenza & Respiratory
High cell concentration banking for seed train reduction on fluoropolymer single use bag
Bioprocess & Manufacture
The current status of autologous & autogenous vaccines development in Europe
Veterinary
From bench to clinical trial: feeding the value chain
Influenza & Respiratory
Scalable in vitro manufacturing of tailored vaccines
Bioprocess & Manufacture
Vaccines for neglected tropical diseases
Emerging Diseases
Why is a Staph aureus vaccine so challenging?
AMR
Development of a new manufacturing platform technology for human vaccines
Bioprocess & Manufacture
Development of a novel agent (MSC-1) to reactivate an immune response by LIF blockade
Immuno-oncology
Norovirus vaccines in development
Emerging Diseases
Overview of QbD application to vaccines development, with practical examples
Bioprocess & Manufacture
Regulatory and operational aspects of GMO vaccines studies
Clinical Development
Vaccine against AECOPD: clinical progress and strategic challenges
AMR
Vaccinomics approach to control vector-borne diseases
Veterinary
Professor Jose De La Fuente, Head Of Genomics Group, Instituto De Investigacion En Recursos Cinegeticos Ronda De Toledo S/NSpain
Development of anti-tick vaccines to control tick-borne viruses
Veterinary
Monitor vaccination studies using Repertoire Sequencing and the IGX Platform
Immuno-oncology
Process development of a novel low-cost liquid rotavirus vaccine to meet global demand
Bioprocess & Manufacture
Update on E.coli vaccine and impact on AMR
AMR
When preparation meets opportunity: reducing the odds of failure in Late Phase
Clinical Development
MVA-VLP as a safe and effective platform for delivery of multi-antigens for infectious diseases and cancer
Immuno-oncology
Case study: Applying artificial intelligence in cancer treatment response prediction
Immuno-oncology
E.coli UTI and bacteremia epidemiology
AMR
Exploration and design of novel vaccination strategies for controlling parasites
Veterinary
HIV vaccine trials: NIH perspective and challenges
Emerging Diseases
How can we achieve sustainable vaccine manufacturing?
Bioprocess & Manufacture
How site’s can be a useful part of protocol development process
Clinical Development
Panel: The role of biomarkers in vaccine development and licensure
Clinical Development
- Pertussis, MenB, Influenza and emerging diseases
- Regulatory requirements
Dr Marco Cavaleri, Head Of Anti-Infectives And Vaccines, EMAUnited Kingdom
Challenges and urgency of developing a GAS vaccine
AMR
Comparing traditional vaccine manufacturing to mRNA vaccine manufacturing
Bioprocess & Manufacture
Epigenome deregulation in cancer
Immuno-oncology
International consortium partnerships to accelerate vaccine product innovation, clinical trials and self-reliance
Emerging Diseases
Representatives from: Europe, Africa, Saudi, North America
New approaches to tackle antimicrobial resistance
Veterinary
Modelling cancer pharmacogenomics
Immuno-oncology
Mucosal vaccines in veterinary species: Lessons from E. coli vaccinations in pigs
Veterinary
Typhoid Conjugate Vaccine
AMR
Dr Sushant Sahastrabuddhe, Director, Enteric Fever, International Vaccine InstituteRepublic Of Korea
Create your personal agenda –check the favourite icon
Chair’s opening remarks
Vaccine Safety
Chair’s opening remarks
Immuno-oncology
Chair’s opening remarks
Veterinary
Chair’s opening remarks
Partnerships
Chair’s opening remarks
Bioprocess & Manufacture
Accelerating vaccine process development and increasing productivity with single use intensified processing and predictive process control - Downstream Processing
Bioprocess & Manufacture
Economics, vaccine development and the burden of animal disease
Veterinary
William Gilbert, Lead Economic Analyst, H2020 SAPHIR Project, University of LiverpoolUnited Kingdom
Panel: Building vaccine confidence and resilient immunization systems – The role of communications
Vaccine Safety
- The role of communications in vaccine hesitancy and confidence?
- How can stakeholders from patient advocates, journalists, healthcare providers, policymakers to industry
- Apply behavioural science insights to shape more effective communications around vaccination and improve vaccination acceptance?
- What are the attributes of a resilient immunization system, and how can we collaborate to manage threats to vaccine confidence and better anticipate and mitigate issues in the future?
Unlocking the potential of oncolytic viruses to target cancer cells
Immuno-oncology
Clinical Updates on Vyriad’s Voyager-V1 Program
World Bank collaboration and its capacity for vaccine trials in emerging countries (strategy and plans)
Partnerships
Accelerating livestock vaccine development for LMICs; How can industry help?
Veterinary
How introduction of single use and high through put equipment in fermentation change the process development way of working?
Bioprocess & Manufacture
Marjorie Monnet, Fermentation Unit Head, Sanofi PasteurUnited States
Systemic delivery of localized combination immuno-gene therapy within the tumour microenvironment
Immuno-oncology
The role of emerging markets in the global supply and demand for vaccines
Partnerships
Bats, horses, pigs, people: One health countermeasures against hendra and nipah viruses
Veterinary
EIB Venture Debt – Financing Innovation and Growth in Life Sciences
Partnerships
- How the European Investment Bank and the EU Join Forces to Fight Infectious Diseases and Support Innovative European SMEs
Exploiting a successful immunization platform to develop advanced immuno-oncology remedies
Immuno-oncology
Comparative analysis of Nipah virus vaccine candidates in pigs
Veterinary
Adult Vaccines – What’s needed for a rapidly changing demographic?
Vaccine Safety
- Same data, different results: an archetype analysis of adult vaccine decision making and uptake in 34 countries
- Adult Immunization Evidence & Policy: Issues for the next decade
- Issues for implementation of adult immunization programs
- Introducing the International Council on Adult Immunization
- Panel with all speakers: Accelerating progress – what do we do differently?
MERS prevention – developing a candidate vaccine for humans and camels
Veterinary
Overcoming antibody drug development challenges
Immuno-oncology
-Translating antibody therapies to the clinic – The devil is in the detail
Panel: Insights on how to implement new business partnership models for international collaboration among vaccine manufacturers and government
Partnerships
International collaborative research and partnering opportunities for vaccine development
Emma Wheatley, Head Of Collaborations And Deputy General Counsel, CEPIUnited Kingdom
Driving successful antibody discovery and development
Immuno-oncology
Recent outbreaks of equine influenza and the potential new strain recommendations from OIE
Veterinary
Vaccines in rural communities
Partnerships
Working towards a universal flu vaccine
Veterinary
What’s next? Working towards Immunology 2.0 and beyond
Keynotes
- How has genomics, virology and epidemiology helped revolutionise the way we develop vaccines?
- New scientific approaches to more targeted bacterial vaccines using computational modelling and mAb mapping
- What progress has been made with all this new information to hand – is it translational?
- What policy considerations and challenges should we anticipate with these technologies? Governmental challenges
Eliminating (or Eradicating) Measles and other Global Infectious Diseases
Keynotes
- Is elimination of measles still viable?
- What’s the vaccinations strategy to get there and how do we maintain this once a disease is eradicated?
- What plans are in place for developing countries?
last published: 24/Oct/19 13:25 GMT
Password must meet the following requirements:
- At least one letter
- At least one capital letter
- At least one number
- Be at least 6 characters
Roxane Feller, Secretary General,
AnimalhealthEurope
Roxane FELLER is Secretary General of AnimalhealthEurope. As the voice of the animal medicines industry in Europe, the association works to highlight the importance of healthy pets and farm animals and to demonstrate the reliability and value of animal health solutions to society. Roxane started...
Dr Elzo Kannekens, Director,
MSD Animal Health
After studying Veterinary Science at Utrecht University, Elzo started as vet in general practise. He returned to the Faculty of Veterinary Science to become lecturer in bovine health management and Quality Assurance management and worked as vet in the university’s bovine health...
Kevin Tiessen, Program Leader - Livestock Health,
International Development Research Centre
As Program Leader of IDRC’s Animal Health program, Dr. Kevin Tiessen and his team are responsible for programming and managing two large partnerships, the: i) Livestock Vaccine Innovation Fund (LVIF), a seven year, CA$57 million partnership between the Bill & Melinda Gates Foundation, Global ...
Theo Kanellos, Director of Business Development & Alliances,
Zoetis
Theo Kanellos qualified as a veterinarian from the Aristotle University of Thessalonica in Greece and has been awarded an MSc in microbiology and PhD in molecular medicine from the University of London. He also has a business diploma from the Ecole Supérieur de Commerce de Paris (ESCP). During his...
Samuel Thevasagayam, Deputy Director, Global Development,
The Bill & Melinda Gates Foundation
Samuel Thevasagayam leads the Livestock Initiative within Agriculture Development Program at the Bill & Melinda Gates Foundation. He oversees implementation of foundation’s strategy in animal health, livestock genetics, and livestock production & markets
Prior to joining the foundation in...
Aaron Schacht, Executive Vice President - Innovation, Regulatory And Business Development,
Elanco Animal Health
Aaron Schacht serves as executive vice president, Innovation, Regulatory, and Business Development at Elanco. In this role, he oversees global R&D, regulatory, business development and nutritional health. With a focus on ideas, products and technologies that address customers’ unmet needs, he...
Dr Jean-Charles Cavitte, Research Policy Officer,
European Commission
Jean-Charles Cavitte holds a doctorate in veterinary medicine from "École Nationale Vétérinaire d'Alfort" and a subsequent specialisation at the French national school of veterinary services. Dr Cavitte background is mainly on veterinary public health. He is now research policy...
Dr Melanie Saville, Director Of Vaccine Development- Uk,
CEPI
Melanie Saville joined the Coalition for Epidemic Preparedness Innovations (CEPI) in November 2017 initially as Head of Clinical development and now as Director Vaccine Development. Melanie is a physician specialized in virology with more than 18 years’ experience in the development and licensure...
Pedro Alsina, Public Affairs Lead Spain,
Sanofi Pasteur
Pedro Alsina is Country Public Affairs Director for Sanofi Pasteur Spain. Pedro started his professional career as marketing specialist at 3M Health Care. Due to his strong interest on Public Health he started in the vaccines field in 1997 by joining Pasteur Mérieux MSD Spain as Scientific Advisor...
Dr Martin Friede, Coordinator, Initiative For Vaccine Research Immunization, Vaccines And Biologicals Department,
WHO
Martin Friede is the coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. In this position Dr Friede provides leadership to WHO’s activities on vaccine research including development of vaccine research policies, strategies and...
Dr Hans Nauwynck, Professor,
Gent University
Hans Nauwynck is a DVM, who did his PhD and directly became nominated as professor at Ghent University in 1993. In 2004, he took the lead of the Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University and became Diplomate at the European College of Pig Health Management. At...
Dr Gregory Glenn, President, Research And Development,
Novavax
Dr. Glenn is President of Research and Development and leads Novavax’ discovery, clinical and regulatory teams with responsibility of the RSV programs, including maternal immunization, an RSV F vaccine for older and high risk adults, and a differentiated adjuvanted recombinant seasonal influenza...
Jacqueline Miller, Vice President And Head, Clinical Randd,
GSK Biologicals
Dr. Jacqueline Miller is currently the Head of Clinical R&D and Epidemiology at GlaxoSmithKline Vaccines’ US R&D Center in Rockville, Maryland. After attending medical school at Northwestern University’s Feinberg School of Medicine, and subsequently training in pediatrics and pediatric...
Volker Gerdts, Director And Chief Executive Officer,
VIDO-InterVac
Dr. Volker Gerdts is the Associate Director of Research at the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan in Saskatoon, SK Canada. Dr. Volker Gerdts received a DVM in 1994 from Hanover Veterinary School and a German PhD...
Dr Paolo Nuciforo, Head Molecular Oncology Group,
Vall d'Hebron Institute of Oncology
Paolo Nuciforo, MD, PhD, board certified Pathologist, is the Principal Investigator of the Molecular Oncology group at Vall d`Hebron Institute of Oncology (VHIO). He has 15+ years of experience in oncology translational medicine and drug development both in academic and pharmaceutical...
Dr Niels Pallisgaard, Molecular Biologist,
Zealand University Hospital
Niels Pallisgaard has worked more than 20 years with clinical molecular Hematology. He has contributed internationally to the standardization of qPCR MRD monitoring of leukemia by chairing the Europe Against Cancer (EAC) reference gene workgroup, by chairing the MPN-EuroNet workgroup on...
Gregory Poland, Director Of Mayo Vaccine Research Group,
Mayo Clinic
Gregory A. Poland, M.D., is the director of Mayo Clinic’s Vaccine Research Group — a state-of-the-art research group and laboratory that investigates issues surrounding vaccine response and novel vaccines important to public health. Dr. Poland holds the academic rank of professor of medicine and...
Dr Wolfgang Philipp, Head Of Unit,
The European Comission
Wolfgang Philipp is the Head of Unit for crisis management and preparedness in health in the Public Health, Country Knowledge, Crisis Management Directorate of the European Commission. His unit is dealing with activities contributing to preparedness and crisis management related to cross-border...
Dr Maria Elena Bottazzi, Co-Director, Texas Children’s Hospital Center for Vaccine Development,
Baylor College of Medicine
Maria Elena Bottazzi, PhD is the Associate Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine in Houston, Texas. She also directs the Research and Administration of the new Section of Pediatric...
Dr Josie Golding, Lead,
Wellcome Trust
Josie Golding is part of the Vaccine Priority Are at Wellcome, an initiative established in 2017. She leads on epidemic preparedness and response across Wellcome, which involves bringing together basic sciences, product development, social sciences, public engagement and policy, to generate more...
Dr Melanie Saville, Director Of Vaccine Development- Uk,
CEPI
Melanie Saville joined the Coalition for Epidemic Preparedness Innovations (CEPI) in November 2017 initially as Head of Clinical development and now as Director Vaccine Development. Melanie is a physician specialized in virology with more than 18 years’ experience in the development and licensure...
Dr Wolfgang Philipp, Head Of Unit,
The European Comission
Wolfgang Philipp is the Head of Unit for crisis management and preparedness in health in the Public Health, Country Knowledge, Crisis Management Directorate of the European Commission. His unit is dealing with activities contributing to preparedness and crisis management related to cross-border...
Dr Jonathan Van-Tam, Deputy Chief Medical Officer,
UK Department of Health
Professor Van-Tam is an internationally recognised flu, vaccine and respiratory expert. During his 25-year career, he has advised the World Health Organization, the UK Government and The European Centre for Disease Prevention and Control on influenza and other respiratory virus infections.
He...
Dr Fumie Griego, Deputy Director General And Chief Operating Officer,
International Federation of Pharmaceutical Manufacturers and Associations
Fumie Griego is IFPMA’s Deputy Director General and Chief Operating Officer. She joined IFPMA in May 2017 to lead IFPMA’s strategic planning, as well as policy and research for the organization with a focus on health policy and economics topics such as value of medicines, government pricing and...
Dr Robert Johnson, Director, Influenza And Emerging Infectious Diseases Division,
HHS/BARDA
Robert Johnson, Ph.D., is the Director of the Influenza and Emerging Infectious Diseases Division of Biomedical Advanced Research Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human...
Laszlo Radvanyi, President And Scientific Director,
Ontario Institute for Cancer Research
Dr. Laszlo Radvanyi brings a strong oncology research background in academia as well as leadership experience in international pharma and biotech, making him an ideal leader for OICR. Laszlo was educated at the University of Toronto, earning a PhD in Clinical Biochemistry in 1996. Laszlo joined...
Dr Gregory Glenn, President, Research And Development,
Novavax
Dr. Glenn is President of Research and Development and leads Novavax’ discovery, clinical and regulatory teams with responsibility of the RSV programs, including maternal immunization, an RSV F vaccine for older and high risk adults, and a differentiated adjuvanted recombinant seasonal influenza...
Geert Mudde, Founder & CSO,
Tyg Oncology Ltd
Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992, he joined the pharmaceutical/biotech industry, where he held several senior...
Dr Cyril Gay, Senior National Program Leader,
A.R.S. National Programs
Dr. Gay obtained a B.Sc. in Chemistry and a Doctor of Veterinary Medicine from Auburn University, and a Ph.D. in Microbiology from The George Washington University. Dr. Gay has worked in the animal health research field for the last 25 years holding several positions of increasing responsibility...
Christopher Parks, Executive Director,
International Aids Vaccine Initiative
Dr. Parks directs IAVI’s research program on the vesicular stomatitis virus (VSV) vaccine vector platform for the development of vaccines against HIV-1 and hemorrhagic fever viruses. He joined IAVI in 2007 to help expand and manage The IAVI Vaccine Design and Development Laboratory and establish...
Dr Jan Poolman, Head Bacterial Vaccine Discovery And Early Development,
Janssen
Dr. Jan Poolman is Head Bacterial Vaccine Discovery and Early Development at Janssen Infectious Diseases and Vaccines, at the Janssen Pharmaceutical Companies of Johnson & Johnson. Jan leads the bacterial vaccines team, which focuses on developing vaccines against the most prevalent antibiotics ...
Christopher Parks, Executive Director,
International Aids Vaccine Initiative
Dr. Parks directs IAVI’s research program on the vesicular stomatitis virus (VSV) vaccine vector platform for the development of vaccines against HIV-1 and hemorrhagic fever viruses. He joined IAVI in 2007 to help expand and manage The IAVI Vaccine Design and Development Laboratory and establish...
Dr Kees Melief, Chief Scientific Officer,
I.S.A. Pharmaceuticals Bv
Professor Cornelis (Kees) JM Melief is emeritus professor of internal medicine specialized in “immunohematology” at Leiden University. Since 2011 he is emeritus professor at LUMC and Chief Scientific Officer (CSO) of ISA Pharmaceuticals, a biotech company specializing in development of synthetic...
Ab Osterhaus, Director, Research Center For Emerging Infections And Zoonoses (Riz),
University of Veterinary Medicine Hannover
Professor Osterhaus is the newly appointed Director of Research Center for Emerging Infections and Zoonoses (RIZ) at University of Veterinary Medicine Hannover. Prior to this role he was the Head of the Department of Viroscience at Erasmus MC Rotterdam, and Professor of Wildlife Virology and Virus...
Dr Jan Spaas, Chief Executive Officer,
Global Stem Cell Technology
Jan H. Spaas was born in 1986 and his high school majors were Latin and Mathematics. He is a passionate horseback rider and won a 2-fold bronze medal at European Championships and 3-fold bronze medal at Belgian Championships for juniors and young riders (show jumping). He graduated as a...
Annelies Wilder-Smith, Professor Of Infectious Disease, Principal Investigator For Vaccine Preventable Diseases & Emerging,
Nanyang Technological University
Professor Annelies Wilder-Smith is Full Professor with Tenure for Infectious Diseases Research at Lee Kong Chian School of Medicine (LKCMedicine) which she joined in May 2013. Since July 2017, she only maintains a part-time position at LKC, as she is working as Consultant for Arboviral Diseases at...
Grace Chen, Deputy Chief Of The Clinical Trials Program In The Vrc,
National Institutes of Health
Grace L. Chen, MD is the Deputy Chief of the Clinical Trials Program at the Vaccine Research Center, NIAID. She leads protocol development for the VRC and has served as Principal Investigator and Associate Investigator on Phase I and II IND clinical trials studying vaccines and monoclonal...
Leonard Friedland, Vice President, Scientific Affairs And Public Health Vaccines, North America,
GSK
Leonard Friedland is Vice President, Director Scientific Affairs and Public Health, Vaccines North America at GSK. Dr. Friedland has held many positions in clinical research and development with GSK since 2003, specializing in infectious disease vaccination. Prior to his work at GSK, Dr. Friedland...
Joanna Miller, Chief Scientific Officer,
Cell Therapy Sciences
Dr Joanna Miller is a Science Director and Research Manager with experience of Regenerative Medicine in the Veterinary field. She is a biochemist and cell biologist by training with a background of commercial research in both large pharma and SMEs. She worked for Glaxo as a Cell Biologist...
Gabrielle Breugelmans, Director Of Research,
Access to Medicine Foundation
Gabrielle Breugelmans joined the Access to Medicine Foundation in 2018 as Director of Research where is responsible for the direction and delivery of the Access to Medicine Foundation’s research programmes and other research activities. She is an infectious disease epidemiologist with broad...
Professor Lana Kandalaft, Director, Center Of Experimental Therapeutics,
University of Lausanne
Prof. Lana Kandalaft is one of the key members of the Swiss Cancer Center in Lausanne Switzerland. She is currently the Cheffe de Service (Director) of the Center of Experimental Therapeutics, an integrated structure of clinical services, manufacturing facilities and laboratory platforms in the...
Nathalie Landry, Executive Vice President,
Medicago
Ms. Landry oversees a multidisciplinary team in charge of preclinical and clinical studies, development of analytical methods and product characterization. Her group has conducted several clinical trials in the United States and Canada evaluating both pandemic and seasonal plant-made Influenza...
Dr Dolores Gavier-Widén, Head Of Department,
National Veterinary Institute SVA
Dr Dolores Gavier-Widén, Head, Department of Pathology and Wildlife Diseases, National Veterinary Institute (SVA), Sweden Dr Dolores Gavier-Widén is a veterinary pathologist and holds a MSc and a doctorate in veterinary medicine from the University of California, Davis, USA. Dr Gavier-Widén’s...
Dr Christopher Netherton, Principal Investigator,
The Pirbright Institute
Chris Netherton leads the African Swine Fever Vaccinology group and has been investigating different aspects of the life cycle of African swine fever virus (ASFV) for over twenty years. His studies on ASFV have encompassed analysis of individual viral proteins right through to herd transmission...
Valérie Lecouturier, Head of Research Unit,
Sanofi Pasteur
She obtained her PhD in Molecular Virology in Lyon (University Claude Bernard Lyon I) in 1998 after studying the structure function of measles virus hemagglutinin in Fabian Wild’s lab. She then joined the lab of Eric Cohen in University of Montreal to work on HIV Vpu protein for a post-doctoral...
Markus Waldhuber, Co-Founder And Scientific Leader,
Adivo GmbH
Dr Markus WaldhuberMarkus Waldhuber is Co-Founder and Scientific Leader of adivo. His areas of responsibility include antibody discovery of proprietary and partnered programs, identification of target opportunities as well as technology development.Markus has a biochemical background and received...
Dr Arturo Reyes Sandoval, Associate Professor,
University of Oxford
Dr. Arturo Reyes-Sandoval is an Associate Professor at the Nuffield Department of Medicine (NDM) in the University of Oxford. He is a Principal Investigator at the Jenner Institute. Arturo is currently leading a group working on a research program to develop vaccines for 5 neglected and emerging...
Emanuele Montomoli, Professor In Public Health University Of Siena And Chief Scientific Officer,
VisMederi
Emanuele Montomoli is Full Professor on Public Health at the University of Siena in Italy. He received his BSc and MSc in Life Sciences from University of Siena in Italy in 1995 and he earned his MBiochem in 2001. He is also Chief of Scientific Office of VisMederi srl, a private enterprise involved ...
Ulrike Gnad-Vogt, Senior Vice President, Area Head Oncology & Head of Translational Medicine,
CureVac AG
Dr. Ulrike Gnad-Vogt is a board certified medical oncologist and hematologist working in the field of cancer immunotherapy since 2005. Before joining CureVac in 2011, she held positions as global medical leader for early cancer immunotherapies at Merck Serono and as attending medical oncologist at...
Dr Alexander Kort, Senior Vice President Corporate Development,
Themis Bioscience
Alexander Kort is SVP Corporate Development at Themis Bioscience GmbH in Vienna, Austria. His responsibilities include all business development and licensing activities of Themis and oversight of all internal corporate development activities. Alexander has more than 10 years’ experience in the...
Dr Fernando Rodriguez, Head Of The Animal Health Program,
IRTA-CReSA
PhD in Biology (1994), Dr. Rodriguez has devoted his scientific live to explore new avenues to improve vaccinology. His Thesis work was performed at CISA-INIA (Madrid-Spain) working on African swine fever immunology thanks to a Predoctoral thesis from the Bask Government. In 1995 Dr. Rodriguez...
Richard Chin, Chief Executive Officer,
Kindred Biosciences, Inc.
Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Richard has developed several drugs for immune diseases, including Lucentis®, Xolair®, Tysabri®, and Rituxan®. These products have yielded over $10 billion...
Sune Justesen, Chief Scientific Officer,
Immunitrack ApS
For more than a decade responsible for developing and maintaining and one of the largest collections of recombinant Major Histocompability Complex I and II molecules at the University of Copenhagen in the laboratory of Proff. Søren Buus. In a decade long NIH funded effort, these molecules were used ...
Teresa Lambe, Associate Professor,
University of Oxford
Prof. Lambe’s research interest lies in the development of efficacious vaccines, principally toward influenza and outbreak pathogens, with a particular focus on CCHFV, Nipah virus, and filoviruses.
Prof. Lambe has extensive knowledge in the assessment of naturally acquired and post-vaccination...
Dr Erin Spiegel, Director Of Scientific Affairs,
PharmaJet
Dr. Erin Spiegel is the Director of Scientific Affairs at PharmaJet, a medical device company in Golden, Colorado, that has developed Needle-Free Injection technologies. Prior to joining PharmaJet, Erin worked as a Senior Regulatory Specialist at Evergreen Research and Scientific Consultant at CBR...
Sarah Gilbert, Professor Of Vaccinology,
University of Oxford
Professor Sarah Gilbert leads the Jenner Institute’s influenza vaccine programme and has completed the first clinical efficacy study of an influenza vaccine designed to work through cellular immunity, in which vaccine efficacy and a protective T cell phenotype was demonstrated. The ...
Dr Kate Broderick, Vice President, Research And Development,
Inovio Pharmaceuticals
Dr Broderick has a broad background in the product development and device development DNA therapeutic and drug delivery field, with specific expertise in in vivo DNA vaccine animal studies and product development in relation to electroporation. Her particular area of focus is electroporation...
Carel Du Marchie Sarvaas, Executive Director,
HealthforAnimals
Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years. He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4...
Dr Martin Friede, Coordinator, Initiative For Vaccine Research Immunization, Vaccines And Biologicals Department,
WHO
Martin Friede is the coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. In this position Dr Friede provides leadership to WHO’s activities on vaccine research including development of vaccine research policies, strategies and...
Mark Pearson, Deputy Director, Employment, Labour And Social Affairs,
O.E.C.D.
Mark Pearson is Deputy Director of Employment, Labour and Social Affairs at the Organisation for Economic Co-operation and Development (OECD).
Prior to 2014, he was Head of the Health Division where he helped countries to improve their health systems by providing internationally comparable...
David Anderson, CSO,
VBI Vaccines
A dynamic and well-published immunologist with broad expertise in the areas of vaccine development, autoimmunity and tumor immunology, Dr. Anderson joined VBI full time in 2009 from Harvard Medical School, where he held a position as Assistant Professor. Dr. Anderson is an inventor of much of the...
Wayne Koff, President And Chief Executive Officer,
The Human Vaccines Project
Wayne C. Koff, PhD, is founding President & CEO of the Human Vaccines Project, a public-private partnership with the goal of decoding the human immune system to accelerate development of vaccines and immunotherapies for major infectious diseases and cancers. Prior to joining the Project, he...
Carlota Dobano Lazaro, Associate Research Professor,
Isglobal
Carlota Dobaño is the head of the Malaria Immunology Group and coordinates large multicenter studies on naturally acquired and experimentally immunity to malaria. She is also faculty on MSc Global Health, Vaccinology Module.
In 1992 she graduated in Pharmacy and Pharmacology at the Universitat de...
Morena D'Alise, Lead Immunologist,
Nouscom
Morena is the Senior Scientist of Immunology Lab at Nouscom, a biotech dedicated to the development of next generation cancer immunotherapies. Her focus is Preclinical Immunology for Vaccine and Immunotherapy. Prior to Nouscom, Morena was a Scientist at Okairos, a company developing genetic...
Dr Anders Høgset, Chief Scientific Officer,
PCI Biotech
Anders Høgset is Chief Scientific Officer (CSO) in PCI Biotech AS in Oslo since April 2001, and he was also CEO in the company from 2004 to 2008. He holds a PhD in biochemistry from the University of Oslo. Earlier employments include: senior scientist at The Norwegian Radium Hospital in...
Dr Baptiste Dungu, Chief Executive Officer,
Onderstepoort Biological Products
A qualified South African veterinarian, with a PhD in vaccinologist(University of Pretoria), currently Head of Strategy and Business Development for MCI Santé Animale, largest African biopharmaceutical company, in Morocco.
Dr Tobias Kamphuis, Project Leader Viral Vaccines,
Janssen
Tobias Kamphuis is compound development team leader for the Universal. Influenza Vaccine at Janssen Vaccines and Prevention in Leiden, the Netherlands. He has a background in Molecular Biology and received his PhD from the University of Groningen, the Netherlands before joining Janssen in 2012.
Juliana Cassataro, Research,
Instituto de Investigaciones Biotecnologicas
Dr. Juliana Cassataro leads a team at Instituto de Investigaciones Biotecnológicas (IIB-University of San Martin-UNSAM, CONICET) San Martin, Argentina working on vaccine development against infectious diseases. She is at present Principal Researcher from the National Council for Scientific and...
Alexandre Le Vert, Chief Executive Officer And Co-Founder,
Osivax
Alexandre has broad experience in healthcare ranging from research and development to commercialization of vaccines and therapeuticsHe is an experienced entrepreneur in biotech and innovation.Alexandre is a Board Member of several biotech companies in France and in the US.
Ab Osterhaus, Director, Research Center For Emerging Infections And Zoonoses (Riz),
University of Veterinary Medicine Hannover
Professor Osterhaus is the newly appointed Director of Research Center for Emerging Infections and Zoonoses (RIZ) at University of Veterinary Medicine Hannover. Prior to this role he was the Head of the Department of Viroscience at Erasmus MC Rotterdam, and Professor of Wildlife Virology and Virus...
Philip Beer, Physician Scientist And Precision Oncology Specialist,
Sanger Institute
Dr Philip Beer is a physician scientist and precision oncology specialist who operates across the commercial, academic and healthcare sectors. Philip holds diverse positions united by the singular goal of leveraging genomic technologies to improve outcomes for cancer patients. Current roles include ...
Dr Cyril Gay, Senior National Program Leader,
A.R.S. National Programs
Dr. Gay obtained a B.Sc. in Chemistry and a Doctor of Veterinary Medicine from Auburn University, and a Ph.D. in Microbiology from The George Washington University. Dr. Gay has worked in the animal health research field for the last 25 years holding several positions of increasing responsibility...
Dr Jan Poolman, Head Bacterial Vaccine Discovery And Early Development,
Janssen
Dr. Jan Poolman is Head Bacterial Vaccine Discovery and Early Development at Janssen Infectious Diseases and Vaccines, at the Janssen Pharmaceutical Companies of Johnson & Johnson. Jan leads the bacterial vaccines team, which focuses on developing vaccines against the most prevalent antibiotics ...
Charles Lutsch, AVP R,
Sanofi Pasteur
Charles Lutsch, PhD is Associate Vice President R&D Sanofi Pasteur Inc., USA & Head R&D Global Health Vaccine Center of Innovation based at IDRI, Seattle, WA.
Charles, occupied a variety of positions within biopharmaceutical R&D operations;
he was heading R&D at Shantha...
Geert Mudde, Founder & CSO,
Tyg Oncology Ltd
Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992, he joined the pharmaceutical/biotech industry, where he held several senior...
Imraan Munshi, Executive Director And Global Communications Lead For Vaccines,
MSD
Imraan Munshi is Global Communications Lead – Vaccines for Merck & Co, Inc. (Merck) leading the development and implementation of global communications strategies and programs in support of the Company’s vaccine brands, portfolios and investigational vaccines. Munshi develops and conducts...
Dr Melanie Saville, Director Of Vaccine Development- Uk,
CEPI
Melanie Saville joined the Coalition for Epidemic Preparedness Innovations (CEPI) in November 2017 initially as Head of Clinical development and now as Director Vaccine Development. Melanie is a physician specialized in virology with more than 18 years’ experience in the development and licensure...
Dr Hanneke Schuitemaker, Vice President And Head Of Viral Vaccine Discovery And Translational Medicine,
Janssen
Hanneke Schuitemaker is the Global Head of Viral Vaccine Discovery and Translational Medicine in the Infectious Disease and Vaccines Therapeutic Area of Janssen and Professor in Virology at the Academic Medical Center of the University of Amsterdam (since 2004). She joined Crucell on September...
Marion Gruber, Director Of Office For Vaccines,
FDA
Marion F. Gruber, PhD is the Director of the Office of Vaccines Research and Review (OVRR) in the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. In this position, directs the review, monitoring, and evaluation of investigational new drug applications and biologic ...
Dr Jan Poolman, Head Bacterial Vaccine Discovery And Early Development,
Janssen
Dr. Jan Poolman is Head Bacterial Vaccine Discovery and Early Development at Janssen Infectious Diseases and Vaccines, at the Janssen Pharmaceutical Companies of Johnson & Johnson. Jan leads the bacterial vaccines team, which focuses on developing vaccines against the most prevalent antibiotics ...
Noemi Garcia Del Blanco, Head of Veterinary Biologicals and Emerging therapies,
European Medicines Agency
Noemi is a veterinarian with post graduate qualifications in the field of microbiology and infectious diseases. She has been working for more than fifteen years within the area of animal health, including development and regulation of vaccines and other biological veterinary medicinal...
Dr Mel Munro, Project Manager, Biologicals Regulatory Affairs,
Triveritas Limited
Mel Munro joined the animal health consultancy group Triveritas in 2002 after completing a PhD in Transmissible Spongiform Encephalopathies in London. She has worked in Veterinary Medicinal Product development ever since. During her career she has been involved in the development and registration...
Rosario Bullido, Head of Vet Inmuno Medicines Assessment Unit,
Aemps
Head of Immunological/Biological Veterinary Medicines Assessment Unit in theSpanish Medicines and Medical Devices Agency (Spain)Ph D in Veterinary Medicine. Member of veterinary medicinal European expert groups as Immunological Working Party (IWP) of EMA and 15V group European...
Francois Dalencon, Department Director,
Sanofi Pasteur
François Dalençon obtained his PhD in Pharmaceutical Science in 1995 (Paris XI Chatenay Malabry, France) on protein incorporation into lipid bilayer. He was temporary assistant professor in Université Lyon I, School of Pharmacy, between 1995 and 1997 working on DNA vectorization and Pharmaceutical...
Jens-Peter Marschner, Chief Medical Officer,
Zelluna Immunotherapy
Jens-Peter Marschner is CMO of Zelluna since June 1st, 2019. Before Zelluna he filled several leading positions in Clinical Development of big pharma and smaller biotech, e.g. Merck KGaA Germany, Affimed and Abbvie. Over the last 10 years Jens-Peter’s focus was and is on immune oncology. He was...
Guus Rimmelzwann, Alexader Von Humboldt Professor,
University of Veterinary Medicine Hannover
Guus F. Rimmelzwaan works at the intersection of human and veterinary medicine. He is an internationally eminent immunologist specialising in virus research, especially on influenza viruses that can occur in both humans and animals and potentially be transmitted from animals to humans and vice...
Prof Jaap Wagenaar, Professor Veterinary Medicine,
University of Utrecht
Jaap Wagenaar was trained as veterinarian and completed his PhD study at Utrecht University and the USDA-National Animal Diseases Center, Ames, IA, US. In 1996 he started his research group at the Central Veterinary Institute (now: Wageningen Bioveterinary Research) in Lelystad, the Netherlands, on ...
Dr Max Søgaard, Director, Process Development,
ExpreS2ion Biotechnologies
T. Max M. Søgaard, Cand. Scient, Ph.D, Director of Process Development, Expres2ion BiotechnologiesMax Søgaard joined Expres2ion Biotechnologies in 2013 to set up a protein purification and characterisation department. Working closely with clients he has since helped to convert non-cGMP, lab-scale...
Sanjay Vashee, Associate Professor,
J. Craig Venter Institute
Sanjay Vashee is an Associate Professor in the Synthetic Biology Group at the J. Craig Venter Institute in Rockville, MD. After joining JCVI in 2003, Dr. Vashee helped the Synthetic Biology Group develop synthetic genomics methods and technologies that led to the creation of a synthetic organism...
Lucilla Steinaa, Principle Scientist,
International Livestock Research Institute
Lucilla Steinaa obtained her MSC in 1992 after which she worked as a scientist at a hospital with HIV and in a in a Biotech company in Denmark., where she obtained her PhD in 2001 in the immunological area from University of Copenhagen. She later worked in another Biotech company with recombinant...
Sarah Gilbert, Professor Of Vaccinology,
University of Oxford
Professor Sarah Gilbert leads the Jenner Institute’s influenza vaccine programme and has completed the first clinical efficacy study of an influenza vaccine designed to work through cellular immunity, in which vaccine efficacy and a protective T cell phenotype was demonstrated. The ...
Helena Florindo, Assistant Professor, Group Leader of the BioNanoSciences, Drug Delivery & Immunotherapy research group,
University of Lisbon
Helena Florindo graduated in Pharmaceutical Sciences in 2003 (University of Lisbon) and obtained her Ph.D. degree in Pharmaceutical Technology in 2008 (University of Lisbon), in collaboration with the University of London.Currently, she is an Assistant Professor with tenure and habilitation in the...
Dr Koert Stittelaar, General Manager Viroclinics Xplore,
Viroclinics Biosciences B.V.
Dr Koert Stittelaar joined Viroclinics Biosciences in 2006. Previous to this he was a Postdoc at the Virology Department at Erasmus MC Rotterdam in vaccine and pathogenesis research projects including HIV, dengue and poxvirus preclinical research. Koert was trained in medical microbiology at the...
Prof David Goldblatt, Professor Of Vaccinology And Immunology And Director Of Clinical Research And Development,
UCL
David Goldblatt is Professor of Vaccinology and Immunology and Head of the Immunobiology Section at the Great Ormond Street Institute of Child Health, University College London (UCL) where he also holds the role of Institute Deputy Director for NHS Engagement. He is a Consultant Paediatric...
Mikkel Nissum, R&D Quality Site Lead,
GSK Vaccine
Mikkel Nissum | R&D Quality Site Lead | GSK Vaccines | ItalyMikkel has been taking on different assignments in GSK vaccines in Preclinical R&D and Technical Development . Currently, he is the R&D Quality Site Lead at GSK Vaccines. Mikkel was trained as analytical chemist and biochemist...
Rutger Vandiest, Global Head of Sales,
Bavarian Nordic
Rutger Vandiest is Sr Director –Global head of sales, CDMO at Bavarian Nordic. Being for more than 20 years in the biopharmaceutical industry, he is a preeminent expert in biopharmaceutical outsourcing. Gained aseptic processing experience in top-tier pharma companies and leading global sales and...
Dr Ivan Martinez Forero, Regional Clinical Director,
MSD
Ivan has an MD from Universidad Nacional, Colombia, and received his PhD from Universidad de Navarra, Spain. He was also a Cancer Immunotherapy Fellow. Universidad de Navarra, Spain. He is an expert in translational oncology with over 30 papers published in the field.
Renate Lamprecht, Portfolio Manager,
Afrigen Biologics (Pty) Ltd
Renate Lamprecht is a scientist in the adjuvant R&D division of Afrigen Biologics. Renate has a keen interest in designing next generation recombinant and subunit vaccines with a focus on animal diseases. Afrigen has access to a range of adjuvants formulations that are made available for...
Rasmus Mortensen, Head of TB Vaccine Research,
Statens Serum Institut
Dr. Mortensen received his doctorate in immunology and vaccinology at University of Copenhagen and is the head of preclinical TB vaccine development at Statens Serum Institut in Copenhagen, Denmark. His group is studying protective immunological mechanisms of vaccine mediated immunity against Mtb...
Dr Martin Friede, Coordinator, Initiative For Vaccine Research Immunization, Vaccines And Biologicals Department,
WHO
Martin Friede is the coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. In this position Dr Friede provides leadership to WHO’s activities on vaccine research including development of vaccine research policies, strategies and...
Dr Steven Reed, Founder, Distinguished Scientist,
Infectious Disease Research Institute
Steve Reed is the Founder, President, and CSO of the Infectious Disease Research Institute (IDRI). His academic appointments include Professor of Medicine at Cornell University Medical College in New York and Research Professor of Pathobiology at the University of Washington. He serves on several...
Gerald Voss, Scientific Director,
TuBerculosis Vaccine Initiative
Dr. Gerald Voss is the Scientific Director of the TuBerculosis Vaccine Initiative (TBVI, Lelystad, The Netherlands) and the Executive Director of SciPeo Sprl, Science & People, a life sciences and coaching consultancy. Gerald recently served as the Interim Director of the Global HIV Vaccine...
Don Diamond, Professor, Department Of Hematology And Hematopoietic Cell Transplantation,
City Of Hope
Don J. Diamond, Ph.D., is a professor in the Department of Hematology & Hematopoietic Cell Transplantation. His research includes developing vaccines to combat hematologic malignancies, solid tumors, and infectious pathogens such as the herpesvirus, cytomegalovirus (CMV) HIV.The prospect of an...
Anders Lilja, Senior Vice President Of Technical Development,
Hookipa Biotech
Anders Lilja is SVP Technical Development at HOOKIPA. He is responsible for developing HOOKIPA’s promising product candidates from research through GMP manufacturing. While at HOOKIPA, he led the development of our cytomegalovirus vaccine candidate HB-101 through the phase 1 clinical trial. Prior...
Andrea Carfi, Senior Director, Antigen Design And Selection, Infectious Diseases,
Moderna Therapeutics
Andrea Carfi, Ph.D., is the head of research for infectious disease at Moderna, leading all research efforts for infectious disease targets. The infectious disease division focuses on discovery and development of vaccines as well as therapeutic and prophylactic approaches against infectious disease ...
Philip Beer, Physician Scientist And Precision Oncology Specialist,
Sanger Institute
Dr Philip Beer is a physician scientist and precision oncology specialist who operates across the commercial, academic and healthcare sectors. Philip holds diverse positions united by the singular goal of leveraging genomic technologies to improve outcomes for cancer patients. Current roles include ...
Melisa Carpio, Global Technology Consultant,
Sartorius Stedim Biotech GmbH
Melisa is a Global Technology Consultant for the Cell Culture Technologies department at Sartorius Stedim Biotech. In this role, she focuses on the growth and development of single-use bioreactors, including the BIOSTAT RM and STR product lines. She works to continually investigate opportunities...
Louise Cosby, Head Of Virology,
Agri-Food and Biosciences Institute
Education and Career
Professor S. Louise Cosby (SLC) is a graduate (B.Sc. and Ph.D. in Microbiology) of Queen’s University Belfast and was a member of staff for over 30 years. She held the post of Chair of Microbiology in the School of Medicine Dentistry and Biomedical Sciences from 2002 to...
Dr Gregory Glenn, President, Research And Development,
Novavax
Dr. Glenn is President of Research and Development and leads Novavax’ discovery, clinical and regulatory teams with responsibility of the RSV programs, including maternal immunization, an RSV F vaccine for older and high risk adults, and a differentiated adjuvanted recombinant seasonal influenza...
Pauline Verdijk, Clinical Research Scientist,
Intravacc
Pauline Verdijk, PhD, is the senior clinical research scientist at Intravacc in Bilthoven, the Netherlands. At Intravacc, she is leading the clinical development of novel vaccine concepts, including clinical trial design and management. In addition, she provides scientific input in preclinical...
Jonathan Cartoux, Field Application Engineer EMEA LIFE SCIENCES,
ENTEGRIS
Mr. Cartoux joined Entegris in January 2018 as an Application engineering team. He came to Entegris from Merck Millipore Sigma Company, which he joined in 2010. In his current role, Mr. Cartoux’s primary responsibilities include growing the life sciences business with his technical expertise...
Nicholas Kitchin, Senior Vaccine Clinical Research Director,
Pfizer Ltd
Nick qualified as a physician from the University of London in 1991. After a brief early clinical career in anaesthetics, seeking new challenges, Nick joined the pharmaceutical industry in 1994. He started specialising in the field of vaccines in 1998 when he joined Pasteur Mérieux MSD in the UK as ...
Giulio Severi, Research Manager,
Istituto Zooprofilattico Sperimentale Umbria e Marche (IZSUM)
Giulio Severi is doctor in veterinary medicine (DVM) and PhD. At last 20 years was working in animal health care whit a special focus in autogenous and autologous vaccines reserch, development and producton. Is the author or co-author of over seventy publications. He is specialized in animal...
Hadil Es-Sbai, CEO,
CR2O
Extensive experience in the pharmaceutical and clinical research domain, specialised in designing and implementing international clinical trials (phase I-IV). Co-founded several companies in the Life Sciences and fully geared towards making innovative treatments accessible to those in need.
Alexander Koglin, Founder,
NTxBio
Dr. Alex Koglin is the Chief Science and Technology Officer and co-founder of NTxBio located in Santa Fe, New Mexico and is a co-inventor of NTxpressTM. Alex has an immense background in structural biology and natural product biosynthesis with many peer reviewed papers in high-impact journals. He...
Dr Maria Elena Bottazzi, Co-Director, Texas Children’s Hospital Center for Vaccine Development,
Baylor College of Medicine
Maria Elena Bottazzi, PhD is the Associate Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine in Houston, Texas. She also directs the Research and Administration of the new Section of Pediatric...
Raphael Simon, Senior Director,
Pfizer
The goal of Dr. Simon’s research is the development of vaccines to prevent invasive infections with bacterial pathogens, including Salmonella enterica and Klebsiella pneumoniae. A main area of focus is the development of polysaccharide:protein glycoconjugate vaccines based on the O polysaccharide...
Dr Andreas Neubert, Vice President Vaccines,
IDT Biologika
Dr. Andreas Neubert has more than 30 years of experience in vaccine development and manufacturing. He worked about 10 years on R&D projects for different viral vaccines. He received extensive training on Vaccine Manufacturing, Gene Technology including Current Good Manufacturing Practice...
Joan Seoane, Director of Translational Research,
Vall d'Hebron Institute of Oncology
Joan Seoane is a Group Leader and Director of the Preclinical &Translational Research Co-Program at the Vall d'Hebron Institute of Oncology (VHIO) within the Vall d'Hebron University Hospital since 2011. In 1998, Joan obtained his PhD in Biochemistry and Molecular Biology from the...
Sean Tucker, Chief Scientific Officer And Vice President Research,
Vaxart
Vaxart is a privately held, clinical-stage company developing tablet vaccines. The company’s proprietary delivery platform is suitable to deliver any recombinant vaccine in oral form and allows rapid development to address emerging threats. Vaxart vaccines can be conveniently...
Eckhardt Petri, Director Global Medical Affairs,
Takeda
Eckhardt Petri is the Global Medical Affairs Lead for a Norovirus Vaccine in development and is, in addition, also leading the European Medical Affairs activities for Takeda’s Vaccines Business Unit. He graduated in 1993 at the Philipps-University Marburg, thereafter took up residency at the...
Daniela Stranges, Senior Manager,
GlaxoSmithKline
Daniela graduated in Chemistry and obtained the PhD in Chemical Sciences at the University of Florence. Since 2006 she has worked in in Technical Research and Development for Novartis Vaccines (now GSK Vaccines) in Siena (Italy), contributing to product and process development for several vaccine...
Barbara Dogan, Director,
Syneos Health
Barbara Dogan is an experienced Director of Regulatory Affairs with particular expertise in regulatory review and consulting for Europe and worldwide. Barbara has more than 30 years professional experience in scientific research, pharmaceutical industry and clinical research organizations. Barbara...
Simona Rondini, Vaccine Development Lead, Copd Vaccine,
GSK Vaccines
Simona Rondini is the COPD Vaccine Development Leader at GSK Vaccines in Siena.She obtained a PhD at the Swiss Tropical Public Health Institute in Basel and continued her post-doctoral studies at Cornell College in New York City.Before moving to GSK Vaccines, she worked at GVGH (GSK Vaccines...
Dr Dennis A Bente, Associate Professor,
University of Texas Medical Branch
Dr. Dennis Bente is an Associate Professor, researcher, and veterinarian. His research focus is on tick-borne hemorrhagic fever viruses such as Crimean-Congo hemorrhagic fever. What makes Dr. Bente’s research most unique is that he and his team are studying this family of diseases under maximum...
Dr Nicola Bonzanni, Chief Scientific Officer,
ENPICOM
Dr. Nicola Bonzanni is Chief Scientific Officer and Co-Founder of ENPICOM BV. During his 10 years of experience as bioinformatic researcher he worked in leading institutions including the Netherlands Cancer Institute and Microsoft Research. He focused on developing new analysis methods for patient...
Ahd Hamidi, Project Director,
Batavia Biosciences
Dr. Ahd Hamidi is a bioprocess technologist currently working as a Project Director at Batavia Biosciences. She has ample experience in vaccine process development (both Upstream and Downstream) and technology transfer in the framework of Global Health. Over the past 20 years, she has been in...
Dr Jan Poolman, Head Bacterial Vaccine Discovery And Early Development,
Janssen
Dr. Jan Poolman is Head Bacterial Vaccine Discovery and Early Development at Janssen Infectious Diseases and Vaccines, at the Janssen Pharmaceutical Companies of Johnson & Johnson. Jan leads the bacterial vaccines team, which focuses on developing vaccines against the most prevalent antibiotics ...
Adrian Wildfire, Scientific Director - Infectious Diseases And Viral Infection Unit,
SGS Life Science Services
Adrian Wildfire, MSc, is the Project Director for Infectious Diseases / Human Challenge Unit within SGS Life Sciences and has a background in communicable diseases stretching back to 1987. He has trained and worked within the fields of bacteriology, virology, parasitology and mycology, obtaining...
Dr Farshad Guirakhoo, Chief Scientific Officer,
GeoVax, Inc.
Before joining GeoVax in 2015, Dr. Guirakhoo served in senior management and scientific roles within the biotechnology industry with Vaxess Technologies, Hookipa Biotech, Sanofi Pasteur, Acambis, Inc. and OraVax, Inc. In his scientific career, Dr. Guirakhoo has filed over 90 patent applications and ...
Anguraj Sadanandam, Team Leader,
Institute of Cancer Research
Sadanandam completed his interdisciplinary Ph.D. from the USA, and continued postdoc with Professors Joe Gray and Douglas Hanahan. Briefly worked at Swiss Institute of Bioinformatics. He is currently a tenured Team Leader (Associate Professor) at the Institute of Cancer Research (ICR), London. He...
Thomas Verstraeten, Managing Director P95,
P95
Thomas Verstraeten graduated as MD from Ghent University in 1987 and obtained a degree in Tropical Medicine from the Institute of Tropical Medicine in Antwerp in 1988. After about 10 years working in the field in emergency relief in Africa and HIV/STD research and surveillance in both Belgium and...
Dr Alasdair Nisbet, Head Of Vaccine Research, Moredun Research Institute,
Moredun Research Institute
Alasdair Nisbet is Head of the Vaccines Pillar at Moredun. He graduated from Glasgow University with a BSc in Agricultural Zoology, followed by a PhD in Biochemistry. After postdoctoral periods at Aberdeen University and the University of Melbourne, he joined Moredun in 2004. Throughout his...
Mary Marovich, Director Of Vaccine Research Program,
NIAID, NIH
Dr. Mary Anne Marovich joins NIAID's Division of AIDS as the new director of the Vaccine Research Program, where she will lead the development and coordination of clinical and preclinical research on HIV vaccines. Marovich comes to NIH from the...
Prof Harris Makatsoris, Professor,
Cranfield University
Harris is Professor of Manufacturing Operations in the Sustainable Manufacturing Systems Centre at Cranfield University. He has extensive expertise in process engineering, manufacturing systems, operations and control and has been developing A.I. controlled flow reactor systems for functional...
William Smith, Chief Executive Officer,
Alliance for Multispecialty Research LLC
Dr. William Smith is the Founder, President, and Principal Investigator of VRG and NOCCR, the AMR centers in Knoxville, TN and New Orleans, LA. He is also one of the original founders of AMR. Dr. Smith is board certified in Internal Medicine, Critical Care Medicine, Nephrology, and Cardiology. He...
Dr Miles Carroll, DD,
Public Health England
Miles Carroll joined Public Health England (formerly known as the Health Protection Agency)) as Deputy Director, Head of Research at Porton Down in September 2008. In his current role he has strategic and operational responsibilities to ensure that the Department is at the forefront of...
Marion Gruber, Director Of Office For Vaccines,
FDA
Marion F. Gruber, PhD is the Director of the Office of Vaccines Research and Review (OVRR) in the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. In this position, directs the review, monitoring, and evaluation of investigational new drug applications and biologic ...
Prof Andrew Gorringe, Scientific Leader,
P.H.E.
Andrew Gorringe is a Scientific Leader at PHE. He leads the Pathogen Immunology Group which is developing novel methods of characterising antibody and complement interactions with bacterial pathogens. He has performed leading research on the role of fimbriae in B. pertussis vaccines and current...
Dr Martin Friede, Coordinator, Initiative For Vaccine Research Immunization, Vaccines And Biologicals Department,
WHO
Martin Friede is the coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. In this position Dr Friede provides leadership to WHO’s activities on vaccine research including development of vaccine research policies, strategies and...
Christoph Kröner, Head of IVAC Mutanome,
BioNTech RNA Pharmaceuticals GmbH
Christoph is the Head of IVAC Mutanome Lead Structure at BioNTech RNA Pharmaceuticals GmbH. He completed his PhD in bioorganic chemistry at the University of Stuttgart, after having completed his Diploma in chemistry at the same institution.
Dr Zdenko Herceg, Head, Section Of Mechanisms Of Carcinogenesis,
International Agency for Research on Cancer (IARC/WHO)
As Section and Group Head at International Agency for Research on Cancer/World Health Organization, I lead a multi-faceted research programme on epigenetic mechanisms of carcinogenesis and identification and validation of epigenetic-based biomarkers of environmental exposures and cancer risk. The...
Dr Maria Elena Bottazzi, Co-Director, Texas Children’s Hospital Center for Vaccine Development,
Baylor College of Medicine
Maria Elena Bottazzi, PhD is the Associate Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine in Houston, Texas. She also directs the Research and Administration of the new Section of Pediatric...
Dr S Ravetkar, Executive Director,
Serum Institute of India Ltd
Dr. S.D. Ravetkar is an Executive Director and member of Board with Serum Institute of India Ltd. Apart from his Doctorate he holds degrees in Management and Finance. He has authored various research articles in national and international journals. He is also on advisory board of various national...
Anissa Boumlic-Courtade, Associate Director Vaccine And Viral Therapies Emea,
MERCK
Dr. Anissa Boumlic-Courtade is the Associate Director of EMEA vaccine and viral therapies segment development for Merck. She is focused on partnering with EMEA developers of vaccine and viral therapies to solve manufacturing challenges and reduce time to clinic. Anissa Boumlic has 5 years virology...
Dr Martin Mengel, ,
Global-Health Consulting
Dr. Martin Mengel is an independent consultant in vaccinology and life sciences with a special focus on emerging markets. He helps companies from the vaccines and pharma industries and international agencies in the development of their business strategy and product portfolio. He also develops...
Dr Turki Almugaiteeb, Chief Technical Officer,
RPDC Innovations
Turki I. Almugaiteeb, Ph.D. is the Director of Healthcare and Life Science Division at RPDC. Prior to that, he completed his post-doctorate at the University of Texas in Biomedical Engineering where he designed an innovative device that can isolate cancer stem cells for drug discovery research and ...
Bruno Gonzalez Zorn, Head of the Antimicrobial Resistance Unit,
Complutense University of Madrid
Prof. Bruno Gonzalez-Zorn, DVM, PhD is Head of the Antimicrobial Resistance Unit at the Complutense University in Madrid, and Adjunct Professor of Biotechnology at the University for Development Studies in Ghana. He gained his DVM in 1996 studying in Spain and Germany and his european PhD in 2001...
Pedro Ballester, Group Leader,
INSERM
Following a first degree in Physics and MSc in Information Processing and Neural Networks, Pedro Ballester completed a part-time PhD at Imperial College London on geophysical data mining and inference. Subsequently, he was awarded a Junior Research Fellowship at the University of Oxford and then...
Dr Eric Cox, Director Of The Laboratory Of Immunology,
University of Ghent
Graduated in 1983 as doctor in Veterinary Medicine at the University of Gent. After being assistant in animal physiology at the University of Antwerp between and assistant in veterinary virology and in immunology, he became appointed assistant-professor at the Laboratory of Immunology in 1993 and ...
Imraan Munshi, Executive Director And Global Communications Lead For Vaccines,
MSD
Imraan Munshi is Global Communications Lead – Vaccines for Merck & Co, Inc. (Merck) leading the development and implementation of global communications strategies and programs in support of the Company’s vaccine brands, portfolios and investigational vaccines. Munshi develops and conducts...
Shruthi Naik, Founder and Vice President, Comparative Oncology,
Vyriad
Dr. Naik is a researcher in the Department of Molecular Medicine at Mayo Clinic. She has extensive knowledge and experience developing oncolytic virus based cancer immunotherapies, having both designed and led translational studies of novel oncolytic immunotherapy products currently in clinical...
Dr Cyril Gay, Senior National Program Leader,
A.R.S. National Programs
Dr. Gay obtained a B.Sc. in Chemistry and a Doctor of Veterinary Medicine from Auburn University, and a Ph.D. in Microbiology from The George Washington University. Dr. Gay has worked in the animal health research field for the last 25 years holding several positions of increasing responsibility...
David Hipkiss, Chief Executive Officer,
Enesi Pharma Limited
David joined Enesi Pharma in September 2017 as CEO. Prior to Enesi, he was Chief Business Officer of Circassia Pharmaceuticals, and a member of its Senior Management Team with global group responsibility for all M&A, partnering and licensing activities.Before joining Circassia, David was CEO...
Charles Lutsch, AVP R,
Sanofi Pasteur
Charles Lutsch, PhD is Associate Vice President R&D Sanofi Pasteur Inc., USA & Head R&D Global Health Vaccine Center of Innovation based at IDRI, Seattle, WA.
Charles, occupied a variety of positions within biopharmaceutical R&D operations;
he was heading R&D at Shantha...
Amelie Boulais, Vaccine Platform Marketing Manager,
Sartorius Stedim Biotech
Amélie Boulais is Marketing Manager – new generation vaccines – at Sartorius Stedim Biotech. She is analyzing the trends of the vaccine industry in order to define best-in-class solutions with the required associated Process Development support and related services for vaccine applications.She...
Imraan Munshi, Executive Director And Global Communications Lead For Vaccines,
MSD
Imraan Munshi is Global Communications Lead – Vaccines for Merck & Co, Inc. (Merck) leading the development and implementation of global communications strategies and programs in support of the Company’s vaccine brands, portfolios and investigational vaccines. Munshi develops and conducts...
Isabel De La Mata, Principal Advisor For Health And Crisis Management,
European Commission
Dr Isabel de la Mata is currently the Principal Adviser for Health and Crisis Management in the European Commission. Previously, she worked as Counsellor for Health and Consumers at the Permanent Representation of Spain to the EU, as Deputy Director General for Health Planning at the Spanish...
Gráinne O'Rourke, Former Head Of Communications,
Irish Cancer Society
Gráinne O'Rourke has worked in the private, public and not-for-profit sectors over the course of a 30-year career. Gráinne worked in a variety of businesses from enterprise-creation to animation before taking on the establishment of a green-field operation in DIT, a higher education institution ...
Shruthi Naik, Founder and Vice President, Comparative Oncology,
Vyriad
Dr. Naik is a researcher in the Department of Molecular Medicine at Mayo Clinic. She has extensive knowledge and experience developing oncolytic virus based cancer immunotherapies, having both designed and led translational studies of novel oncolytic immunotherapy products currently in clinical...
Johanna Roth, Project Officer,
EDCTP – European & Developing Countries Clinical Trials Partnership
Johanna joined EDCTP in March 2018 as a Project Officer in the Calls & Grants team. In this position, she is responsible for managing the HIV portfolio of funded projects, running calls for proposals, management of peer-review and grant preparations. Prior to joining EDCTP, she obtained her PhD ...
Musa Mulongo, Senior Program Specialist,
IDRC
Currently a Senior Program Specialist with the Animal Health Program at the International Development and Research Centre (IDRC), Musa is an expert in infectious disease immunology and vaccine discovery having worked in Kenya, the United Kingdom and Canada. He has extensive experience in the...
David Krige, VP, Translational Medicine,
Psioxus Therapeutics Ltd
David is the VP of Translational Medicine at PsiOxus Therapeutics, a cancer gene therapy company based in Oxford, UK. He gained his PhD in Biochemistry from the University of London, and has held a number of roles in the biotech industry, most recently as Head of Biomarkers at Immunocore.
Dr S Ravetkar, Executive Director,
Serum Institute of India Ltd
Dr. S.D. Ravetkar is an Executive Director and member of Board with Serum Institute of India Ltd. Apart from his Doctorate he holds degrees in Management and Finance. He has authored various research articles in national and international journals. He is also on advisory board of various national...
Christopher Broder, Professor And Chair,
Uniformed Services University
Christopher C. Broder received his B.S. (1983) and M.S. (1985) degrees from the Florida Institute of Technology, Melbourne. He earned his Ph.D. from the University of Florida, Gainesville (1989) establishing a molecular-pathogenic model for the flesh-eating Group A streptococci. He began his...
Gergely Krajcsi, Investment Officer,
European Investment Bank
As an Investment Officer in the Growth Capital & Innovation Finance Division of the European Investment Bank, Gergely focuses on the life sciences sector. In particular, he also looks after the Infectious Diseases Finance Facility, a programme backed by the European Commission representing a...
Dr Alexander Kort, Senior Vice President Corporate Development,
Themis Bioscience
Alexander Kort is SVP Corporate Development at Themis Bioscience GmbH in Vienna, Austria. His responsibilities include all business development and licensing activities of Themis and oversight of all internal corporate development activities. Alexander has more than 10 years’ experience in the...
Rebecca Mclean, Post Doctoral Researcher and Project Manager,
The Pirbright Institute
Rebecca graduated from Harper Adams University with a BSc (Hons) degree in Bioveterinary Science. She went on to obtain a PhD from the University of Edinburgh whilst based at Moredun Research Institute. Here she developed and characterised a novel lentiviral vaccine vector for the use in...
Lois Privor-Dumm, Director, Policy, Advocacy And Communications, IVAC,
Johns Hopkins Bloomberg School of Public Health
Lois Privor-Dumm is the Director, Policy, Advocacy & Communications at the International Vaccine Access Center (IVAC) at Johns Hopkins Bloomberg School of Public Health and Secretariat Director for the International Council on Adult Immunization (ICAI). Ms. Privor-Dumm brings extensive...
Dr Martin Friede, Coordinator, Initiative For Vaccine Research Immunization, Vaccines And Biologicals Department,
WHO
Martin Friede is the coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. In this position Dr Friede provides leadership to WHO’s activities on vaccine research including development of vaccine research policies, strategies and...
Gregory Poland, Director Of Mayo Vaccine Research Group,
Mayo Clinic
Gregory A. Poland, M.D., is the director of Mayo Clinic’s Vaccine Research Group — a state-of-the-art research group and laboratory that investigates issues surrounding vaccine response and novel vaccines important to public health. Dr. Poland holds the academic rank of professor of medicine and...
Paolo Bonanni, Professor, Director,
University of Florence
Paolo Bonanni is a Full Professor of Hygiene in the Faculty of Medicine and the Director of the Specialization School for MDs in Hygiene and Preventive Medicine at the University of Florence, Italy.
Professor Bonanni graduated in Medicine and Surgery (MD) in 1985 and was awarded two...
Dr Gerd Sutter, Full Professor And Chair For Virology, Director, Department Of Veterinary Sciences,
Lmu Munich
Gerd Sutter is Professor and Chair of Virology in the Department of Veterinary Sciences of which he is the Director at the Ludwig-Maximilians Universität München (LMU Munich), Germany. Prof. Gerd Sutter´s primary research fields include: Poxvirus infections, and mechanisms of (pox-)viral...
Stephen Beers, Associate Professor,
University Of Southampton
Stephen Beers joined the University of Southampton, Faculty of Medicine in 2002. His research group is interested in how antibodies work to result in tumour regression. Their research is currently focused on how host factors such as the tumour microenvironment and obesity/nutrition affect cancer...
Johanna Roth, Project Officer,
EDCTP – European & Developing Countries Clinical Trials Partnership
Johanna joined EDCTP in March 2018 as a Project Officer in the Calls & Grants team. In this position, she is responsible for managing the HIV portfolio of funded projects, running calls for proposals, management of peer-review and grant preparations. Prior to joining EDCTP, she obtained her PhD ...
Gergely Krajcsi, Investment Officer,
European Investment Bank
As an Investment Officer in the Growth Capital & Innovation Finance Division of the European Investment Bank, Gergely focuses on the life sciences sector. In particular, he also looks after the Infectious Diseases Finance Facility, a programme backed by the European Commission representing a...
Dr S Ravetkar, Executive Director,
Serum Institute of India Ltd
Dr. S.D. Ravetkar is an Executive Director and member of Board with Serum Institute of India Ltd. Apart from his Doctorate he holds degrees in Management and Finance. He has authored various research articles in national and international journals. He is also on advisory board of various national...
Zahra Jawad, Group Leader Discovery Technology,
Agenus
Zahra Jawad received her doctoral training at the University of Cambridge in protein evolution and protein engineering. She developed phage display of zinc fingers in the chemistry department of the University of Cambridge, before moving to Domantis and phage display of domain antibodies. Zahra...
Mercedes Mourino, Laboratory and Emerging Diseases Senior Manager,
Zoetis
Mercedes Mouriño is the Laboratory and Emerging Infectious Diseases Senior Manager at Global Biologics Research, Zoetis.Mercedes received her degree in Biology and her PhD in Microbiology from the University of Barcelona, Spain. Currently, Mercedes supervises the Spanish R&D laboratory group...
Dayn Amade, CEO,
Kamaleon
Dayn Amade is the CEO of Kamaleon Mozambique and the creator of the Tablet Comunitario – also known as the Community Tablet www.tabletcomunitario.org, a mobile technology platform that can be towed by a vehicle or non-vehicle to rural communities with the purpose of increasing digital...
Barbara Holzer, Lead, Universal Flu Vaccine Studies,
The Pirbright Institute
Dr Holzer joined The Pirbright Institute in 2009 and has acquired extensive experience working with high-risk animal pathogens such as Rinderpest, PPRV or NSDV in large animals. She is accomplished at delineating and defining the immune response following viral infection or vaccination with...
Gregory Poland, Director Of Mayo Vaccine Research Group,
Mayo Clinic
Gregory A. Poland, M.D., is the director of Mayo Clinic’s Vaccine Research Group — a state-of-the-art research group and laboratory that investigates issues surrounding vaccine response and novel vaccines important to public health. Dr. Poland holds the academic rank of professor of medicine and...
Immaculada Margarit, Head Antigen Design,
GSK Vaccines
Dr. Immaculada Margarit received a degree in Biological Sciences at the University of Barcelona and the University of Bari. She obtained a PhD in Human Genetics at the University of Rome. Following a period at ENI-Milano where she worked on protein engineering of recombinant enzymes, she moved to...
Wayne Koff, President And Chief Executive Officer,
The Human Vaccines Project
Wayne C. Koff, PhD, is founding President & CEO of the Human Vaccines Project, a public-private partnership with the goal of decoding the human immune system to accelerate development of vaccines and immunotherapies for major infectious diseases and cancers. Prior to joining the Project, he...
Dr Jonathan Van-Tam, Deputy Chief Medical Officer,
UK Department of Health
Professor Van-Tam is an internationally recognised flu, vaccine and respiratory expert. During his 25-year career, he has advised the World Health Organization, the UK Government and The European Centre for Disease Prevention and Control on influenza and other respiratory virus infections.
He...
Dr Kutub Mahmood, Scientific Director,
Path
Dr. Kutub Mahmood is the Project Director of the Global Vaccine Development Project, at the nonprofit organization PATH, based in Seattle, Washington. Dr. Kutub Mahmood focuses primarily on conducting technical assessment for vaccine manufacturers and providing support to help achieve WHO...
Silke Schepelmann, Principal Scientist,
National Institute for Biological Standards and Control
Dr Silke Schepelmann joined NIBSC in 2008. She is a Principal Scientist in the live viral vaccines sections of the Division of Virology and heads a group of scientists and post-doctoral scientists.
Before working at NIBSC, Silke was a post-doc at the Royal Free & University College London...
James Goodson, Senior Measles Scientist, Accelerated Disease Control and VPD Surveillance Branch, Global Immunization Division,
CDC
James Goodson: James Goodson is an epidemiologist at the US Centers for Disease Control and Prevention (CDC). He attended the Johns Hopkins University School of Public Health, where he was awarded a Master of Public Health degree in Epidemiology with a Certificate in International Humanitarian...
